Panno speaks on recent changes, page-18

As a micro-cap biotech, it is possible they want to protect themselves from being taken over. Considering the disruptive and blockbuster nature of the technology, it would be far more profitable to keep it in-house and remain in control. There is also the consideration that the technology is a threat to the massive amounts of capital sunk into existing developmental drugs and technologies by big pharma in which case ddrnai is at risk of being bought and stymied. I think they have had impressive efficacy results for some time, even during the Nasdaq listing but want to develop it themselves. Under these circumstances secrecy prevails.